{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:23:44Z","timestamp":1790835824960,"version":"4.1.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>\n                      Considering the limitations of the current approaches to colorectal cancer (CRC) screening, scientists strived to find noninvasive and more powerful biomarkers for the early diagnosis of CRC. Nowadays, there are different sources of biomarkers for CRC diagnosis. Blood-based samples including circulating cell-free tumor DNA (ctDNA) and DNA extracted from leukocytes in peripheral blood might be promising sources of noninvasive cancer biomarkers such as cancer-specific methylation patterns. In this study, we aimed to evaluate the noninvasive early diagnosis of CRC via quantitative promotor methylation analysis of\n                      <jats:italic toggle=\"yes\">SDC2<\/jats:italic>\n                      gene in whole blood.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      Sixty-five CRC patients and 65 healthy participants were enrolled to assess promoter methylation of\n                      <jats:italic toggle=\"yes\">SDC2<\/jats:italic>\n                      gene in whole blood using the methylation quantification endonuclease-resistant DNA (MethyQESD) technique.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Our findings demonstrated drastic hypermethylation of\n                      <jats:italic toggle=\"yes\">SDC2<\/jats:italic>\n                      in blood samples from CRC subjects (37.91%) compared with non-malignant individuals (17.02%) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). The sensitivity for detection of CRC by methylation of\n                      <jats:italic toggle=\"yes\">SDC2<\/jats:italic>\n                      was 81.54%, with a speci\ufb01city of 69.23%. The ROC curve analysis demonstrated that the AUC was 0.847 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), indicating that the status of\n                      <jats:italic toggle=\"yes\">SDC2<\/jats:italic>\n                      promoter methylation in whole blood is an excellent biomarker of CRC diagnosis. Furthermore, our results showed that methylation level in CRC patients significantly increased in higher tumor stages, demonstrating that an increased percentage of methylation is correlated with tumor progression (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">SDC2<\/jats:italic>\n                      promoter methylation status in blood samples is a valuable cancer biomarker and holds high power and accuracy in distinguishing CRC patients from healthy subjects in the early stages of the disease.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1072_22","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T08:08:03Z","timestamp":1667290083000},"page":"S354-S358","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Analysis of SDC2 gene promoter methylation in whole blood for noninvasive early detection of colorectal cancer"],"prefix":"10.4103","volume":"18","author":[{"given":"Goli","family":"Siri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Alesaeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed Esmaeili","family":"Dizghandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrang","family":"Alani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meysam","family":"Mosallaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Soosanabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-35-20241021","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-35-20241021","doi-asserted-by":"crossref","first-page":"101174","DOI":"10.1016\/j.tranon.2021.101174","article-title":"Global colorectal cancer burden in 2020 and projections to 2040","volume":"14","author":"Xi","year":"2021","journal-title":"Transl Oncol"},{"key":"R3-35-20241021","first-page":"89","article-title":"Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors","volume":"14","author":"Rawla","year":"2019","journal-title":"Prz Gastroenterol"},{"key":"R4-35-20241021","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00432-015-1928-z","article-title":"Early detection of colorectal cancer: From conventional methods to novel biomarkers","volume":"142","author":"Vatandoost","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"R5-35-20241021","doi-asserted-by":"crossref","first-page":"84","DOI":"10.21037\/tgh.2019.12.13","article-title":"Programmed colorectal cancer screening decreases incidence and mortality","volume":"4","author":"Rosell\u00f3","year":"2019","journal-title":"Transl Gastroenterol Hepatol"},{"key":"R6-35-20241021","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3389\/fpubh.2014.00210","article-title":"Colorectal cancer screening: Tests, strategies, and perspectives","volume":"2","author":"Stracci","year":"2014","journal-title":"Front Public Health"},{"key":"R7-35-20241021","doi-asserted-by":"crossref","first-page":"n1855","DOI":"10.1136\/bmj.n1855","article-title":"Screening and prevention of colorectal cancer","volume":"374","author":"Kanth","year":"2021","journal-title":"BMJ"},{"key":"R8-35-20241021","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3390\/cancers5020676","article-title":"Epigenetics and colorectal cancer pathogenesis","volume":"5","author":"Bardhan","year":"2013","journal-title":"Cancers"},{"key":"R9-35-20241021","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2217\/epi-2022-0067","article-title":"Epigenetics and its therapeutic potential in colorectal cancer","volume":"14","author":"Oryani","year":"2022","journal-title":"Epigenomics"},{"key":"R10-35-20241021","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41575-019-0230-y","article-title":"Epigenetics of colorectal cancer: Biomarker and therapeutic potential","volume":"17","author":"Jung","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R11-35-20241021","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.3390\/curroncol28060411","article-title":"Screening for colorectal cancer leading into a new decade: The \u201croaring '20s\u201d for epigenetic biomarkers?","volume":"28","author":"Almeida-Lousada","year":"2021","journal-title":"Curr Oncol"},{"key":"R12-35-20241021","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.3390\/biom11111722","article-title":"Novel methylation biomarkers for colorectal cancer prognosis","volume":"11","author":"Gutierrez","year":"2021","journal-title":"Biomolecules"},{"key":"R14-35-20241021","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3390\/ijms23020852","article-title":"Novel diagnostic biomarkers in colorectal cancer","volume":"23","author":"Zygulska","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R15-35-20241021","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1002\/ijc.26246","article-title":"Calpain-6 is an endothelin-1 signaling dependent protective factor in chemoresistant osteosarcoma","volume":"130","author":"Marion","year":"2012","journal-title":"Int J Cancer"},{"key":"R16-35-20241021","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/onc.2013.328","article-title":"RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2","volume":"33","author":"Sun","year":"2014","journal-title":"Oncogene"},{"key":"R17-35-20241021","doi-asserted-by":"crossref","first-page":"35692","DOI":"10.1074\/jbc.M109.054254","article-title":"Syndecan-2 functions as a docking receptor for pro-matrix metalloproteinase-7 in human colon cancer cells","volume":"284","author":"Ryu","year":"2009","journal-title":"J Biol Chem"},{"key":"R18-35-20241021","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.7150\/jca.34944","article-title":"DNA methylation biomarkers in stool for early screening of colorectal cancer","volume":"10","author":"Chen","year":"2019","journal-title":"J Cancer"},{"key":"R19-35-20241021","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1158\/1055-9965.EPI-17-0153","article-title":"Stool DNA test of methylated syndecan-2 for the early detection of colorectal neoplasia","volume":"26","author":"Niu","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R20-35-20241021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-017-0426-3","article-title":"Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer","volume":"9","author":"Oh","year":"2017","journal-title":"Clin Epigenetics"},{"key":"R21-35-20241021","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.2147\/CMAR.S300861","article-title":"SDC2 and TFPI2 Methylation in Stool Samples as an Integrated Biomarker for Early Detection of Colorectal Cancer","volume":"13","author":"Zhang","year":"2021","journal-title":"Cancer Manag Res"},{"key":"R22-35-20241021","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cca.2020.01.010","article-title":"A novel plasma based early colorectal cancer screening assay base on methylated SDC2 and SFRP2","volume":"503","author":"Zhao","year":"2020","journal-title":"Clin Chim Acta"},{"key":"R23-35-20241021","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/15592294.2017.1356957","article-title":"Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples","volume":"12","author":"Bart\u00e1k","year":"2017","journal-title":"Epigenetics"},{"key":"R24-35-20241021","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/labinvest.2008.100","article-title":"MethyQESD, a robust and fast method for quantitative methylation analyses in HNPCC diagnostics using formalin-fixed and paraffin-embedded tissue samples","volume":"88","author":"Bettstetter","year":"2008","journal-title":"Lab Invest"},{"key":"R26-35-20241021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1052-5157(03)00054-0","article-title":"Fecal occult blood test screening for colorectal cancer","volume":"12","author":"Bond","year":"2002","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"R27-35-20241021","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2796.2011.02399.x","article-title":"Colorectal cancer screening","volume":"270","author":"Bretthauer","year":"2011","journal-title":"J Intern Med"},{"key":"R28-35-20241021","first-page":"143","article-title":"Is unsedated colonoscopy gaining ground over sedated colonoscopy?","volume":"110","author":"Zhang","year":"2018","journal-title":"J Natl Med Assoc"},{"key":"R29-35-20241021","doi-asserted-by":"crossref","first-page":"217","DOI":"10.7150\/jca.5829","article-title":"Colonoscopy for colorectal cancer screening","volume":"4","author":"Young","year":"2013","journal-title":"J Cancer"},{"key":"R30-35-20241021","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3389\/fgene.2020.00844","article-title":"Circulating cell-free nucleic acids as epigenetic biomarkers in precision medicine","volume":"11","author":"Rahat","year":"2020","journal-title":"Front Genet"},{"key":"R31-35-20241021","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/14737159.2019.1613891","article-title":"Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis-an update","volume":"19","author":"Moln\u00e1r","year":"2019","journal-title":"Expert Rev Mol Diagn"},{"key":"R32-35-20241021","doi-asserted-by":"crossref","first-page":"a019505","DOI":"10.1101\/cshperspect.a019505","article-title":"Epigenetic determinants of cancer","volume":"8","author":"Baylin","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"R33-35-20241021","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3892\/br.2014.237","article-title":"DNA methylation as an early diagnostic marker of cancer","volume":"2","author":"Dong","year":"2014","journal-title":"Biomed Rep"},{"key":"R35-35-20241021","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12967-019-1853-z","article-title":"Crosstalk between tumor cells and lymphocytes modulates heparanase expression","volume":"17","author":"Theodoro","year":"2019","journal-title":"J Transl Med"},{"key":"R36-35-20241021","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1586\/erm.13.31","article-title":"Circulating peripheral blood mononuclear cells exhibit altered miRNA expression patterns in pancreatic cancer","volume":"13","author":"Frampton","year":"2013","journal-title":"Exp Rev Mol Diagn"},{"key":"R37-35-20241021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-14-54","article-title":"A panel of genes methylated with high frequency in colorectal cancer","volume":"14","author":"Mitchell","year":"2014","journal-title":"BMC Cancer"},{"key":"R38-35-20241021","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.7150\/jca.57114","article-title":"Blood leukocytes methylation levels analysis indicate methylated plasma test is a promising tool for colorectal cancer early detection","volume":"12","author":"Chen","year":"2021","journal-title":"J Cancer"},{"key":"R39-35-20241021","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1002\/cam4.2475","article-title":"Multiplex methylated DNA testing in plasma with high sensitivity and specificity for colorectal cancer screening","volume":"8","author":"Zhao","year":"2019","journal-title":"Cancer Med"},{"key":"R40-35-20241021","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.2147\/CMAR.S300861","article-title":"SDC2 and TFPI2 Methylation in stool samples as an integrated biomarker for early detection of colorectal cancer","volume":"13","author":"Zhang","year":"2021","journal-title":"Cancer Manag Res"},{"key":"R41-35-20241021","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12876-021-01759-9","article-title":"Colorectal cancer screening using a stool DNA-based SDC2 methylation test: a multicenter, prospective trial","volume":"21","author":"Kim","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"R42-35-20241021","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13148-019-0642-0","article-title":"Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA","volume":"11","author":"Han","year":"2019","journal-title":"Clin Epigenetics"},{"key":"R43-35-20241021","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3389\/fgene.2020.00643","article-title":"Aberrant DNA methylation of SEPT9 and SDC2 in stool specimens as an integrated biomarker for colorectal cancer early detection","volume":"11","author":"Zhao","year":"2020","journal-title":"Front Genetics"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1072_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:40:32Z","timestamp":1787067632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1072_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":40,"journal-issue":{"issue":"Suppl 2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1072_22","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}